Form 4 for KLRS Kalaris Therapeutics, Inc.
Accepted 2022-11-18 00:00:00 ET · period of report 2022-11-16 · accession 0000899243-22-036362 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-11-18 | 2022-11-16 | KLRS | VAN BEEK JEROEN B | Chief Commercial Off | S - Sale | $7.50 | -16.1K | 333.7K | -5% | -$120.6K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-11-16 | S | D | 16,074 | $7.50 | 333,726 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.39 to $7.59. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |